Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 

4-Traders Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Novo Nordisk A/S    NOVO B   DK0060534915

Delayed Quote. Delayed  - 09/27 03:43:09 pm
290.6 DKK   -1.89%
09/26 NOVO NORDISK A/ : submits application in the US for including data f..
09/26 NOVO NORDISK A/ : - Share repurchase programme
09/23 NOVO NORDISK A/ : submits application in the US for including data f..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector news 
Latest news on NOVO NORDISK A/S
09/26 NOVO NORDISK A/S : submits application in the US for including data from the two..
09/26 NOVO NORDISK A/S : - Share repurchase programme
09/23 NOVO NORDISK A/S : submits application in the US for including data from the two..
09/21 NOVO NORDISK A/S : semaglutide reduced major cardiovascular events in 1 in 4 typ..
09/20 NOVO NORDISK A/S : Diabetes Campaign Launched in Nigeria to Promote Early Diagno..
09/19 NOVO NORDISK A/S : NovoRapid receives positive CHMP opinion for extended use in ..
09/19 NOVO NORDISK A/S : - Share repurchase programme
09/16 NOVO NORDISK A/S : Victoza lowered the progression of kidney damage in adults wi..
09/16 NOVO NORDISK A/S : NovoRapid® receives positive CHMP opinion for extended use in..
09/15 NOVO NORDISK A/S : Inc. issues voluntary nationwide recall of six batches of Glu..
09/15 NOVO NORDISK A/S : Researchers from Novo Nordisk Report New Studies and Findings..
09/15 NOVO NORDISK A/S : Victoza® lowered the progression of kidney damage in adults w..
09/14 NOVO NORDISK A/S : Saxenda® provides consistent weight loss and improvements in ..
09/13 NOVO NORDISK A/S : Adults with type 2 diabetes treated with Xultophy® (IDegLira)..
09/13 NOVO NORDISK A/S : Semaglutide demonstrated superior HbA1c reduction vs placebo ..
09/12 NOVO NORDISK A/S : Improves Score, Remains at the Top of 2016 Dow Jones Sustaina..
09/12 NOVO NORDISK A/S : - Share repurchase
09/12 NOVO NORDISK A/S : Hypokit batch withdrawn from market
09/09 NOVO NORDISK A/S : Researchers Submit Patent Application, "Dose Setting Mechanis..
09/07 NOVO NORDISK A/S : Johnston County's 2015 was like none other
09/06 NOVO NORDISK A/S : Forum to develop road map for diabetes strategy
09/05 NOVO NORDISK A/S : - Share repurchase programme
09/05 NOVO NORDISK A/S : FDA extends regulatory review period for IDegLira by three mo..
09/05 NOVO NORDISK A/S : Killing non-communicable diseases
09/03 NOVO NORDISK A/S : FDA extends regulatory review period for IDegLira by three mo..
09/02 NOVO NORDISK A/S : FDA extends regulatory review period for IDegLira by three mo..
09/02 NOVO NORDISK A/S : FDA extends regulatory review period for IDegLira by three mo..
09/02 GLOBAL MONOCLONAL ANTIBODIES MARKET : BioPartners, Eli Lilly, Merck Serono, Nov..
09/02 INSIDE THE FDA : Why Sanofi SA (ADR) (NYSE:SNY) IGlarLixi Was Delayed But Novo N..
09/02 NOVO NORDISK A/S : Lars Rebien Srensen to retire as CEO of Novo Nordisk; Lars Fr..
09/02 NOVO NORDISK A/S : insulin pen receives EU approval to treat type 2 diabetes
09/01 NOVO NORDISK A/S : New Proinsulin Study Findings Recently Were Reported by Resea..
09/01 NOVO NORDISK A/S : New Findings Reported from Novo Nordisk Describe Advances in ..
09/01 NOVO NORDISK A/S : Researchers from Novo Nordisk Report Details of New Studies a..
09/01 NOVO NORDISK A/S : Patent Issued for Preparative RP-HPLC Method for Purifying Pe..
09/01 NOVO NORDISK A/S : Caisson Biotech Announces Issuance of US Patent for Factor VI..
09/01 NOVO NORDISK A/S : Studies Conducted at Novo Nordisk on Rheumatoid Arthritis Rec..
09/01 NOVO NORDISK A/S : New Nephrology Findings from Novo Nordisk Reported (Simultane..
09/01 NOVO NORDISK A/S : CEO to step down after 16 years
09/01DJNOVO NORDISK A/S : CEO to Retire at End of the Year -- Update
09/01DJNOVO NORDISK A/S : CEO to Retire at the End of the Year
09/01 NOVO NORDISK A/S : Lars Rebien Sørensen to retire as CEO of Novo Nordisk; Lars F..
08/29 NOVO NORDISK A/S : - Share repurchase programme
08/25 NOVO NORDISK A/S : Patent Issued for Combination Therapy to Enhance NK Cell Medi..
08/25 NOVO NORDISK A/S : Goulston & Storrs Advises Hana Asset Management-Led Consortiu..
08/25 NOVO NORDISK A/S : HFF Closes $305 Million Sale of Novo Nordisk's Headquarters i..
08/22 NOVO NORDISK A/S : Helicopter View of A Sustainable City
08/22 NOVO NORDISK A/S : - Share repurchase programme
08/15 NOVO NORDISK A/S : - Share repurchase programme
08/15 NOVO NORDISK A/S : HQ sold for $305M to Korean investment company
08/12 NOVO NORDISK A/S : ex-dividend day for interim dividend
08/11 NOVO NORDISK A/S : Report Summarizes Type 2 Diabetes Study Findings from Novo No..
08/09 NOVO NORDISK A/S : NHS Scotland approves Novo Nordisk's diabetes drug
08/08 NOVO NORDISK A/S : increased adjusted operating profit by 8% in local currencies..
08/05 CAVERION : Delivers a Large Project for Novo Nordisks New Insulin Production Fac..
08/05 NOVO NORDISK A/S : #WeAreNotWaiting
08/05 NOVO NORDISK A/S : beats 2Q profit forecasts
08/05 CAVERION : delivers a Large Project for Novo Nordisk's new insulin production fa..
08/05DJNOVO NORDISK A/S : 2Q Net Profit Surges 19%
08/05 NOVO NORDISK A/S : increased adjusted operating profit by 8% in local currencies..
08/04 NOVO NORDISK A/S : New Findings from Novo Nordisk in the Area of Type 2 Diabetes..
08/04 NOVO NORDISK A/S : Reports from Novo Nordisk Advance Knowledge in Blood Coagulat..
08/04 NOVO NORDISK A/S : Certain Recombinant Factor VIII Products; Determination To Re..
08/04 NOVO NORDISK A/S : - Share repurchase programme
08/03 NOVO NORDISK A/S : Diabetes drug shunned by Express Scripts Business briefing
08/02NOVO NORDISK A/S : half-yearly earnings release
08/02DJNOVO NORDISK A/S : 2Q 2016 -- Forecast
08/01 NOVO NORDISK A/S : - Share repurchase programme
07/28 NOVO NORDISK A/S : Findings from Novo Nordisk Broaden Understanding of Aleutian ..
07/28 STUDIES FROM NOVO NORDISK YIELD NEW : Effects of BMI, Hypertension,...
07/28 NOVO NORDISK A/S : James Shehan, Former General Counsel at Novo Nordisk, Joins L..
07/28 NOVO NORDISK A/S : Findings from Novo Nordisk in the Area of Ethanol Reported (H..
07/28 DIAMYD MEDICAL : Companion Medical receives FDA clearance
07/25 NOVO NORDISK A/S : - Share repurchase programme
07/23 NOVO NORDISK A/S : 66% of diabetes sufferers unaware
1  2  3  4  5  6  7  8  9  10Next
Advertisement
Financials ( DKK)
Sales 2016 113 146 M
EBIT 2016 49 205 M
Net income 2016 38 289 M
Finance 2016 11 894 M
Yield 2016 2,45%
P/E ratio 2016 19,54
P/E ratio 2017 17,89
EV / Sales 2016 5,16x
EV / Sales 2017 4,87x
Capitalization 596 121 M
More Financials
Chart NOVO NORDISK A/S
Duration : Period :
Novo Nordisk A/S Technical Analysis Chart | NOVO B | DK0060534915 | 4-Traders
Full-screen chart
Technical analysis trends NOVO NORDISK A/S
Short TermMid-TermLong Term
TrendsNeutralBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus HOLD
Number of Analysts 31
Average target price 363  DKK
Spread / Average Target 23%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Lars Rebien Sørensen President & Chief Executive Officer
Göran Albert Ando Chairman
Jesper Brandgaard Chief Financial Officer & Executive Vice President
Mads Krogsgaard Thomsen Chief Science Officer & Executive Vice President
Alan C. Moses Global Chief Medical Officer
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
NOVO NORDISK A/S-25.78%89 965
JOHNSON & JOHNSON14.66%322 232
ROCHE HOLDING LTD.-11.18%215 081
NOVARTIS AG-8.70%211 231
PFIZER INC.4.21%204 049
MERCK & CO., INC.17.66%171 858
More Results